OERLIKON
Oerlikon presents a full range of innovative customized safety components for Battery Electric Vehicles (BEVs), including pioneering heat shields, gas guidance systems, and cell separators. In the event of a battery fire, they improve the heat protection and electrical and mechanical strength of the batteries, which can save passengers' lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606775871/en/
Heat resistant parts such as Oerlikon’s high performance customizable heat shields with superior thermal and electrical insulation increase the safety of battery systems. (Image source: OERLIKON)
Thermal runaway poses a significant challenge in high-performance battery systems and can potentially cause extensive vehicle damage or endanger passengers. “Oerlikon is renowned in the automotive market for its engineering expertise and materials innovation. Now we combine carefully engineered cutting-edge heat-resistant materials with an intelligent design to create thermal insulation systems that are redefining industry standards,” said Marcus Spreckels, Head of Technology TIS.
Highly heat-resistance yet thin and lightweight
The portfolio covers all critical components, from heat shields and gas guidance components to cell separators, to address the needs of any battery system and risk level. They are highly heat-resistant, mechanically durable, and yet ultra-light and thin. They insulate the critical high-voltage infrastructure of the batteries electrically and thermally, thus reducing the likelihood of battery fires spreading to the passenger area at an early stage.
From meeting the basic regulatory standards of the UN Electric Vehicle Safety Regulation (GTR 20) and their often more stringent adoption in individual countries, to exceeding the advanced requirements with Stop/Zero TP and limp-home functionality, the components are both versatile and reliable.
No compromise: customized solutions for any requirement
Unlike other manufacturers, Oerlikon does not offer standard products. Marcus Spreckels: "We develop customized solutions in terms of material and design, taking into account the specific safety requirements of each battery concept without compromising on space or weight."
This is where Oerlikon's experience in automotive engineering comes into play: all components are 3D-moldable, so they can be optimally tailored to the design of the battery system and the vehicle, for maximum protection. Each solution is fully customized and ready to install according to individual requirements.
Combining materials science know-how and automotive experience
Oerlikon's thermal insulation solutions across all safety concepts and battery types on the market represent a new standard in the industry. With their deep knowledge in material science, Oerlikon's engineers have created heat-resistant materials with new properties. Furthermore, Oerlikon's decade-long experience in the automotive market allows customers to benefit from customized solutions from a certified manufacturer who is well-versed in the challenges associated with designing vehicles.
Series production for the entire portfolio has started at the Bremen site in the first quarter of 2024.
IATF 16949 certified and using only mica-free materials in its solutions, Oerlikon is committed not only to advancing vehicle safety, but also to environmental responsibility and ethical materials sourcing.
Visit Oerlikon at the Battery Show Europe in Stuttgart, Hall 8, Booth G85! Come by to explore our pioneering multifunctional thermal insulation solutions and meet the developers.
For interviews or more information, please contact us.
About the Oerlikon Surface Solutions Division
Oerlikon is a leading global provider of surface and additive manufacturing solutions and services. The division offers an extensive portfolio of market-leading thin-film, thermal spray and additive manufacturing technologies, equipment, components and materials. Emission reduction in transportation, maximized longevity and performance of tools and components, increased efficiency and intelligent materials are hallmarks of its leadership. Pioneering technology for decades, the division serves customers with standardized and customized solutions across a worldwide network of more than 170 sites in 37 countries.
With its technology brands – Oerlikon Balzers, Oerlikon Metco and Oerlikon AM – the Oerlikon Surface Solutions division focuses on technologies and services that improve and maximize performance, function, design, reliability and sustainability, which are innovative, game-changing advantages for customers in the automotive, aviation, tooling and general industries and in the luxury, medical, semiconductors, power generation and oil & gas markets.
The division is part of the publicly listed Oerlikon Group (SIX: OERL), headquartered in Switzerland, which has 12,600 employees and generated CHF 2.7 billion in revenue in 2023.
For more information see: www.oerlikon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606775871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom